Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 57
- Registration Number
- NCT06722911
- Locations
- 🇨🇳
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 112
- Registration Number
- NCT06718205
- Locations
- 🇨🇳
Feng Wang, Zhengzhou, Henan, China
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Target Recruit Count
- 30
- Registration Number
- NCT06509009
SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT06422156
Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-14
- Target Recruit Count
- 30
- Registration Number
- NCT06413017
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Target Recruit Count
- 146
- Registration Number
- NCT06409429
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 30
- Registration Number
- NCT06405685
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Target Recruit Count
- 30
- Registration Number
- NCT06404840
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-10-31
- Target Recruit Count
- 57
- Registration Number
- NCT06389760
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06363084
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.